Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | MVD | P53602 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 2/20 | 0.34 |
| ▸ | CTSB | P07858 | 2/20 | 0.34 |
| ▸ | CTSS | P25774 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | CTSD | P07339 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | EYA2 | O00167 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL29062672 | 0.98 | HDAC6 (0.36) | HDAC6HDAC1HDAC2MVDCTSL | |
| SCHEMBL397071 | 0.92 | MVD (0.39) | HDAC6HDAC1HDAC2MVDCTSL | |
| SCHEMBL21069315 | 0.92 | MVD (0.39) | HDAC6HDAC1HDAC2MVDCTSL | |
| SCHEMBL25134161 | 0.92 | MVD (0.39) | HDAC6HDAC1HDAC2MVDCTSL | |
| SCHEMBL25133621 | 0.92 | MVD (0.39) | HDAC6HDAC1HDAC2MVDCTSL | |
| SCHEMBL17873895 | 0.86 | HDAC6 (0.34) | HDAC6HDAC1HDAC2MVDCA14 | |
| Hydrochloric Acid SCHEMBL22492432 | 0.84 | HDAC6 (0.33) | HDAC6HDAC1HDAC2CA14 | |
| SCHEMBL1455952 | 0.83 | MVD (0.38) | HDAC6HDAC1HDAC2MVDCA14 | |
| SCHEMBL6445026 | 0.83 | HDAC6 (0.37) | HDAC6HDAC1HDAC2CTSLCTSB | |
| SCHEMBL256557 | 0.83 | HDAC6 (0.37) | HDAC6HDAC1HDAC2CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1974 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024189550-A1 | PROCESS FOR THE PREPARATION OF ISAVUCONAZONIUM SULFATE AND ITS CRYSTALLINE FORMS | APITORIA PHARMA PRIVATE LIMITED (IN) | 2024-09-19 | — | — | WO | claimed |
| CN-118085005-A | 18 Beta-glycyrrhetinic acid derivative and preparation method and application thereof | 石河子大学 | 2024-05-28 | — | — | CN | claimed |
| US-20240010644-A1 | PROCESS FOR THE PREPARATION OF ISAVUCONAZONIUM SULFATE | CITIBANK, N.A. | 2024-01-11 | — | — | US | claimed |
| CN-107207562-A | Prodrugs of 17 beta-HSD 1 inhibitors | 佛恩多制药有限公司 | 2017-09-26 | — | — | CN | claimed |
| EP-2699557-B1 | 3-(OXAZOL-2-YL-ETHOXY)- AND 3-(THIAZOL-2-YL-ETHOXY)-BENZAMIDE DERIVATIVES AS ANTI-BACTERIAL AGENTS | BIOTA SCIENT MANAGEMENT (AU) | 2017-08-16 | — | — | EP | claimed |
| EP-2621919-B1 | PHENYLQUINAZOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-01-13 | — | — | EP | claimed |
| EP-2199275-B1 | INHIBITOR OF ISCHEMIC DISORDERS | UNIV FUKUOKA (JP) | 2016-01-13 | — | — | EP | claimed |
| US-7776855-B2 | Antimicrobial oxazolidinone prodrugs | JANSSEN PHARMACEUTICA N.V. (BG) | 2010-08-17 | — | — | US | claimed |
| US-20080027053-A1 | ANTIMICROBIAL OXAZOLIDINONE PRODRUGS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-31 | — | — | US | claimed |
| WO-2008014108-A2 | ANTIMICROBIAL OXAZOLIDINONE PRODRUGS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-31 | — | — | WO | claimed |
| EP-0549727-A1 | CARBOXYLIC ACID ESTERS OF RAPAMYCIN | AMERICAN HOME PRODUCTS CORPORATION (US) | 1993-07-07 | — | — | EP | claimed |
| US-5130307-A | Antibody inhibitors; treating organ graft rejection, fungal infections; antiinflammatory agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-07-14 | — | — | US | claimed |
| WO-1992005179-A1 | CARBOXYLIC ACID ESTERS OF RAPAMYCIN | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-04-02 | — | — | WO | claimed |
| WO-2026107097-A1 | SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | ENLAZA THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260132139-A1 | HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4739672-A1 | NEW COMPOUNDS | Aston University (GB) | 2026-05-13 | — | — | EP | disclosed |
| US-4432971-A | HYPOTENSIVE AGENTS AND ANGIOTENSIN INHIBITION | E. R. SQUIBB & SONS, INC. (US) | 1984-02-21 | — | — | US | disclosed |
| EP-0071544-A1 | Phosphonamidate compounds | E.R. Squibb & Sons, Inc. (US) | 1983-02-09 | — | — | EP | disclosed |
| US-4204991-A | Sarcosine1 dehydroalanine8 angiotensin II derivatives | G. D. SEARLE & CO. (US) | 1980-05-27 | — | — | US | disclosed |
| US-3988467-A | Aminoacyl compounds | CIBA-GEIGY CORPORATION (US) | 1976-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027053-A1 | ANTIMICROBIAL OXAZOLIDINONE PRODRUGS | OXA1L, PGLS, CYP51A1 | HDAC6 542/4885HDAC1 82/4885HDAC2 313/4885 |
| US-20240010644-A1 | PROCESS FOR THE PREPARATION OF ISAVUCONAZONIUM SULFATE | STS, MPST, SULT1A1 | HDAC6 452/4885HDAC1 1176/4885HDAC2 1720/4885 |
| US-20260132139-A1 | HIV INHIBITOR COMPOUNDS | SLC11A2, SLC6A15, NHERF1 | HDAC6 2384/4885HDAC1 689/4885HDAC2 1023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.